ALPMF News and Press, Astellas Pharma Inc From 03/29/23

2023-03-29 04:41:23 ET Astellas Pharma ( OTCPK:ALPMF ) ( OTCPK:ALPMY ) is collaborating with Roche Diabetes Care Japan to develop and commercialize Roche's Accu-Chek Guide Me blood glucose monitoring system as a combined product with an app called BlueStar. Astellas s...

2023-03-15 09:10:29 ET The Biden administration on Wednesday published a list of 27 Medicare Part B drugs that will be subject to inflation penalties for the first time in the U.S., including some key pipeline products from AbbVie ( ABBV ), Gilead ( GILD ), and Seagen ( SGEN ...

2023-03-13 08:07:25 ET Bristol Myers ( NYSE: BMY ), Pfizer ( NYSE: PFE ), and AbbVie ( NYSE: ABBV ) are among firms likely to face Medicare price negotiations for some of the key blockbuster medications, Reuters reported Monday, citing five Wall Street and ac...

2023-03-05 12:00:42 ET Cancer drugmaker Seagen ( NASDAQ: SGEN ) had reportedly drawn interest from two pharma giants in less than a year, indicating a bidding war not seen since Horizon Therapeutics ( HZNP ) sparked a buyout fight which Amgen ( AMGN ) won in late 2022. ...

Merck ( NYSE: MRK ) is discontinuing a phase 3 trial of a Keytruda combination treatment for prostate cancer after the study failed its main goals, while another late stage trial of the blockbuster drug did not meet its main objectives to treat a type of lung cancer. Prostate c...

Summary Astellas came in with a mixed set of results, with growth across product segments balanced by challenges in U.S. sales. We are unsure about generic competitors posing a threat to XTANDI's market share. Profitability and economic profit continue to remain a standout, despite ...

The following slide deck was published by Astellas Pharma Inc. in conjunction with their 2023 Q3 earnings call. For further details see: Astellas Pharma Inc. 2023 Q3 - Results - Earnings Call Presentation

Astellas Pharma ( OTCPK:ALPMF ): Q3 GAAP EPS of ¥103.61. Revenue of ¥1.17B. For further details see: Astellas Pharma GAAP EPS of ¥103.61, revenue of ¥1.17B

Summary Taysha has a good chance of scoring with the GAN indication. Astellas may license this program if that happens. However, the FDA's request for more patients is a critical problem. Since its IPO in September 2020, Taysha Gene Therapies ( TSHA ) stock price has b...

The US FDA has accepted supplemental Biologics License Applications from Merck ( NYSE: MRK ), Seagen ( NASDAQ: SGEN ), and Astellas ( OTCPK:ALPMF )( OTCPK:ALPMY ) for a combination of Keytruda (pembrolizumab) and Padcev (enfortumab vedotin) for urotheli...